The under-the-skin treatment received accelerated approval after a clinical trial found that tumors shrank in some participants whose cancer had returned or spread after earlier treatment.
Head and neck squamous cell carcinoma, or HNSCC, begins in the thin, flat cells lining areas such as the mouth, throat and voice box. When the cancer returns or spreads to other parts of the body, it can be difficult to treat. Tumors in these areas can also affect speaking, eating, swallowing and breathing.
As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for certain adults with recurrent or metastatic HNSCC. It is for people whose cancer progressed during or after platinum-based chemotherapy and an immune-based treatment called an anti-PD-(L)1 therapy.
The approval does not cover every type of head and neck cancer. It excludes HPV-associated oropharyngeal cancer, a cancer that begins in the middle part of the throat and is linked to human papillomavirus.
What did the study find?
The approval was based on results from the Phase 1b/2 OrigAMI-4 study. In the trial, 42% of participants had their tumors shrink after treatment. This is called the overall response rate. About 15% of participants had no detectable signs of cancer in the measured tumors, called a complete response; about 28% had a partial response, meaning their tumors shrank but did not disappear.
Among participants whose tumors responded, 56% had a response that lasted longer than six months. A response does not necessarily mean the cancer is cured, and individual results vary.
Because the FDA used its accelerated approval pathway, the approval is based on results that are considered likely to indicate clinical benefit. The company must conduct further research to confirm the treatment’s benefit. A Phase 3 confirmatory study is ongoing.
How does the treatment work?
RYBREVANT FASPRO is given as an injection under the skin. It targets two proteins—EGFR and MET—that can help some cancer cells grow and spread. The treatment is designed to block signals involving both proteins.
The injection includes hyaluronidase, which helps the medicine spread through tissue under the skin. The FDA says this is the first approved dual-targeted treatment in this setting, meaning it acts on both EGFR and MET.
What should patients know about safety?
The FDA lists possible serious risks, including allergic reactions, reactions related to receiving the medicine, lung inflammation, skin problems, eye-related effects and harm to an unborn baby. Patients should review the full prescribing information with their oncology team and report new or worsening symptoms.
For eligible patients whose cancer has progressed after earlier treatments, the approval offers another option. It is not intended for all people with head and neck cancer, and the study results do not guarantee that an individual will respond.
